Glioma Developmental and HyperActive Ras Tumor (DHART) Board

Glioma Developmental and HyperActive Ras Tumor (DHART) Board

Sponsors

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Source Memorial Sloan Kettering Cancer Center
Brief Summary

This study will collect medical records, scan results, and complete surveys to create a registry about people with a neurofibromatosis type 1-associated brain tumor (NF1-associated glioma). A registry is a collection of health information about individuals, and it is usually focused on a specific diagnosis or condition. This registry study will help the researchers learn more about the diagnosis, treatment, and quality of life of people with NF1-associated glioma. The researchers want to understand what happens as a result of different treatments for NF1-associated glioma and how these treatments and the disease itself affect people's lives over a period of time. Information collected during this study could affect how doctors diagnose, test, and treat NF1-associated glioma, and the study could help future patients with this type of cancer.

Overall Status Recruiting
Start Date 2022-07-29
Completion Date 2025-07-29
Primary Completion Date 2025-07-29
Study Type Observational [Patient Registry]
Primary Outcome
Measure Time Frame
Registry of patients with Neurofibromatosis Type 1 (NF1) associated glioma 5 years
Enrollment 50
Condition
Eligibility

Sampling Method:

Non-Probability Sample

Criteria:

Inclusion Criteria: - Clinical diagnosis that meets NIH criteria for NF1 disease by either 1) documented clinical record establishing NF1 or 2) self-reported with supported documentation upon medical record collection. - Willing to have historical and future NF1 related health records sent to registry for review. - Radiologic or pathologically confirmed glioma. - Individuals ≥18 years of age on the date of informed consent. Exclusion Criteria: - Unwillingness to sign informed consent. - No proficiency in English or Spanish as determined by the Investigator.

Gender:

All

Minimum Age:

18 Years

Maximum Age:

N/A

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Anna Piotrowski Principal Investigator Memorial Sloan Kettering Cancer Center
Overall Contact

Last Name: Anna Piotrowski, MD

Phone: 212-610-0483

Email: [email protected]

Location
Facility: Status: Contact:
Memorial Sloan Kettering Basking Ridge (All Protocol Activities) | Basking Ridge, New Jersey, 07920, United States Recruiting Anna Piotrowski, MD 212-610-0483
Memorial Sloan Kettering Monmouth (All protocol activities) | Middletown, New Jersey, 07748, United States Recruiting Anna Piotrowski, MD 212-610-0483
Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale, New Jersey, 07645, United States Recruiting Anna Piotrowski, MD 212-610-0483
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) | Commack, New York, 11725, United States Recruiting Anna Piotrowski, MD 212-610-0483
Memorial Sloan Kettering West Harrison (All Protocol Activities) | Harrison, New York, 10604, United States Recruiting Anna Piotrowski, MD 212-610-0483
Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, 10065, United States Recruiting Anna Piotrowski, MD 212-610-0483
Memorial Sloan Kettering Nassau (All Protocol Activities) | Rockville Centre, New York, 11570, United States Recruiting Anna Piotrowski, MD 212-610-0483
Location Countries

United States

Verification Date

2022-08-01

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Patient Data Yes
Study Design Info

Observational Model: Cohort

Time Perspective: Prospective

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glioma

Clinical Trials on